Faricimab治疗AMD,III期研究达到主要终点

2021-01-28 Allan MedSci原创

Faricimab靶向涉及视力丧失的两种途径-血管生成素2(Ang-2)和血管内皮生长因子A(VEGF-A)。

老年黄斑变性是视网膜最重要的中心区域——黄斑部发生进展性退行性病变的一种疾病,常导致逐渐的视力下降。

罗氏公司的双特异性抗体Faricimab已在两项针对新血管性疾病或湿性老年黄斑变性(nAMD)患者的III期研究中达到了主要终点。Faricimab靶向涉及视力丧失的两种途径-血管生成素2(Ang-2)和血管内皮生长因子A(VEGF-A)。这些途径通过使血管不稳定来驱动视力丧失,这导致形成新的渗漏血管并增加炎症。

罗氏公司首席医学官兼全球产品开发部负责人Levi Garraway说:“这些结果表明,Faricimab作为一种新型药物具有巨大潜力。我们现在已经在四项III期研究中证明了Faricimab治疗老年黄斑变性和糖尿病性黄斑水肿的有效性和安全性”。

仅在美国,nAMD就影响约110万人,并且是60岁以上老年人失明的主要原因。据罗氏称,Faricimab是第一种为眼睛设计的双特异性抗体。

 

原始出处:

http://www.pharmatimes.com/news/roches_faricimab_hits_primary_endpoint_in_two_wet_amd_studies_1361940

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916396, encodeId=ce19191639628, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 10 07:32:45 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021383, encodeId=c78b2021383dc, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Mon Apr 19 11:32:45 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912527, encodeId=0b30191252e23, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Jul 01 04:32:45 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Thu Dec 30 15:32:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316017, encodeId=33b7131601e04, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564146, encodeId=a1d01564146c4, content=<a href='/topic/show?id=c8e8e24552' target=_blank style='color:#2F92EE;'>#faricimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7245, encryptionId=c8e8e24552, topicName=faricimab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f4d15274415, createdName=zhanglin3084, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594856, encodeId=f95c15948568b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921211, encodeId=07a4921211dc, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 22:04:57 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1916396, encodeId=ce19191639628, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 10 07:32:45 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021383, encodeId=c78b2021383dc, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Mon Apr 19 11:32:45 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912527, encodeId=0b30191252e23, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Jul 01 04:32:45 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Thu Dec 30 15:32:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316017, encodeId=33b7131601e04, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564146, encodeId=a1d01564146c4, content=<a href='/topic/show?id=c8e8e24552' target=_blank style='color:#2F92EE;'>#faricimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7245, encryptionId=c8e8e24552, topicName=faricimab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f4d15274415, createdName=zhanglin3084, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594856, encodeId=f95c15948568b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921211, encodeId=07a4921211dc, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 22:04:57 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1916396, encodeId=ce19191639628, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 10 07:32:45 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021383, encodeId=c78b2021383dc, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Mon Apr 19 11:32:45 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912527, encodeId=0b30191252e23, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Jul 01 04:32:45 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Thu Dec 30 15:32:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316017, encodeId=33b7131601e04, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564146, encodeId=a1d01564146c4, content=<a href='/topic/show?id=c8e8e24552' target=_blank style='color:#2F92EE;'>#faricimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7245, encryptionId=c8e8e24552, topicName=faricimab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f4d15274415, createdName=zhanglin3084, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594856, encodeId=f95c15948568b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921211, encodeId=07a4921211dc, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 22:04:57 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-07-01 snf701207
  4. [GetPortalCommentsPageByObjectIdResponse(id=1916396, encodeId=ce19191639628, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 10 07:32:45 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021383, encodeId=c78b2021383dc, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Mon Apr 19 11:32:45 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912527, encodeId=0b30191252e23, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Jul 01 04:32:45 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Thu Dec 30 15:32:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316017, encodeId=33b7131601e04, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564146, encodeId=a1d01564146c4, content=<a href='/topic/show?id=c8e8e24552' target=_blank style='color:#2F92EE;'>#faricimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7245, encryptionId=c8e8e24552, topicName=faricimab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f4d15274415, createdName=zhanglin3084, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594856, encodeId=f95c15948568b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921211, encodeId=07a4921211dc, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 22:04:57 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1916396, encodeId=ce19191639628, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 10 07:32:45 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021383, encodeId=c78b2021383dc, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Mon Apr 19 11:32:45 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912527, encodeId=0b30191252e23, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Jul 01 04:32:45 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Thu Dec 30 15:32:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316017, encodeId=33b7131601e04, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564146, encodeId=a1d01564146c4, content=<a href='/topic/show?id=c8e8e24552' target=_blank style='color:#2F92EE;'>#faricimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7245, encryptionId=c8e8e24552, topicName=faricimab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f4d15274415, createdName=zhanglin3084, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594856, encodeId=f95c15948568b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921211, encodeId=07a4921211dc, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 22:04:57 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-30 zhty5337
  6. [GetPortalCommentsPageByObjectIdResponse(id=1916396, encodeId=ce19191639628, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 10 07:32:45 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021383, encodeId=c78b2021383dc, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Mon Apr 19 11:32:45 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912527, encodeId=0b30191252e23, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Jul 01 04:32:45 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Thu Dec 30 15:32:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316017, encodeId=33b7131601e04, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564146, encodeId=a1d01564146c4, content=<a href='/topic/show?id=c8e8e24552' target=_blank style='color:#2F92EE;'>#faricimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7245, encryptionId=c8e8e24552, topicName=faricimab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f4d15274415, createdName=zhanglin3084, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594856, encodeId=f95c15948568b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921211, encodeId=07a4921211dc, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 22:04:57 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1916396, encodeId=ce19191639628, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 10 07:32:45 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021383, encodeId=c78b2021383dc, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Mon Apr 19 11:32:45 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912527, encodeId=0b30191252e23, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Jul 01 04:32:45 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Thu Dec 30 15:32:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316017, encodeId=33b7131601e04, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564146, encodeId=a1d01564146c4, content=<a href='/topic/show?id=c8e8e24552' target=_blank style='color:#2F92EE;'>#faricimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7245, encryptionId=c8e8e24552, topicName=faricimab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f4d15274415, createdName=zhanglin3084, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594856, encodeId=f95c15948568b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921211, encodeId=07a4921211dc, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 22:04:57 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1916396, encodeId=ce19191639628, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 10 07:32:45 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021383, encodeId=c78b2021383dc, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Mon Apr 19 11:32:45 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912527, encodeId=0b30191252e23, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Jul 01 04:32:45 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996985, encodeId=3ac6199698522, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Thu Dec 30 15:32:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316017, encodeId=33b7131601e04, content=<a href='/topic/show?id=fa2e24053f' target=_blank style='color:#2F92EE;'>#AMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2405, encryptionId=fa2e24053f, topicName=AMD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564146, encodeId=a1d01564146c4, content=<a href='/topic/show?id=c8e8e24552' target=_blank style='color:#2F92EE;'>#faricimab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7245, encryptionId=c8e8e24552, topicName=faricimab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f4d15274415, createdName=zhanglin3084, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594856, encodeId=f95c15948568b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jan 30 12:32:45 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921211, encodeId=07a4921211dc, content=123, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210129/1f7bcc47e19e459f84f162cbdd4e7e4c/f96be1903e2644a39fb32c7d667dbc9c.jpg, createdBy=312c5456893, createdName=ms温馨, createdTime=Fri Jan 29 22:04:57 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-29 ms温馨

    123

    0

相关资讯

Sci Transl Med:视网膜色素上皮细胞移植有望治疗干性年龄相关性黄斑变性

干性年龄相关性黄斑变性(dry age related macular degeneration, dry AMD)是由于视网膜色素上皮 (retinal pigmented epithelium, RPE) 细胞退化并死亡导致中央视力下降的慢性眼病。它是导致中老年人视力下降的重大原因,而且随着社会老龄化趋势的上升,它的发病率也不断升高。

2019年视网膜协会年会:抗体生物聚合物共轭物(ABC)KSI-301治疗湿性AMD

Kodiak Sciences是一家临床阶段的生物制药公司,专门研究用于治疗慢性高流行性视网膜疾病的新疗法,近日宣布,其抗体生物聚合物共轭物(ABC)KSI-301治疗湿性老年黄斑变性(AMD)患者的Ib期临床研究结果将在9月15日举行的Retina Society年会上被披露。

双特异性抗体Faricimab治疗AMD的Ⅲ期数据公布,16周仅需给药1次

AMD是老年群体中常见的一种眼部疾病,影响视力的中心区域——黄斑,这是人视觉最敏锐和最关键的部位。AMD分为“湿性(wet)”和“干性&rd

2019年AAO:新型的蛋白质治疗剂DARPin®治疗AMD的后期数据

新型的蛋白质治疗剂DARPin®治疗AMD的后期数据将在加利福尼亚州旧金山举行的美国眼科学院(AAO)年会被详细介绍。

人工智能识别出7个潜力药物,治疗老年性黄斑变性

此次研究与人工智能公司BenevolentAI合作完成,利用其"Benevolent平台"全面整合了数百万篇科学论文、临床试验以及与AMD相关其他数据集的信息,以寻找潜在的基因治疗靶标和治疗方法。

Nat Biotechnol:干细胞疗法治疗黄斑退化

2015年6月, 86岁的Douglas Waters出现了严重的老年性黄斑变性症状(AMD),导致难以看清东西。几个月之后,他成为了UC Santa Barbara的研究者开发的利用干细胞诱导分化的视觉细胞治疗AMD的临床试验的一员。

拓展阅读

Lancet:双特异性抗体faricimab在湿性或新生血管性年龄相关性黄斑变性(AMD)和糖尿病性黄斑水肿(DME)1年的随访结果

2022年1月24日,罗氏子公司基因泰克(Genentech)宣布,已经在《柳叶刀》上发表了两篇论文,重点介绍了双特异性抗体faricimab在湿性或新生血管性年龄相关性黄斑变性(AMD)和糖尿病性黄

视力下降疗法Faricimab将两次治疗之间的时间延长了四个月

罗氏(Roche)的研究性双特异性抗体Faricimab已被发现可将糖尿病性黄斑水肿(DME)和新生血管性老年黄斑变性(nAMD)患者的治疗间隔延长多达四个月。

罗氏的Faricimab在糖尿病性黄斑水肿研究中大获成功

罗氏公司(Roche)近日宣布,其研究性双特异性抗体Faricimab在糖尿病性黄斑水肿(DME)的两项III期研究中均达到了主要终点。

双特异性抗体Faricimab治疗AMD的Ⅲ期数据公布,16周仅需给药1次

AMD是老年群体中常见的一种眼部疾病,影响视力的中心区域——黄斑,这是人视觉最敏锐和最关键的部位。AMD分为“湿性(wet)”和“干性&rd

罗氏和基因泰克启动3期临床试验:评价双特异性抗体faricimab在湿性老年性黄斑变性中的潜力

Faricimab是研发专门用于治疗视网膜眼病的双特异性抗体,可同时结合并灭活血管生成素-2(Ang-2)和血管内皮生长因子A(VEGF-A)。